MTOR and Angiofibroma: By incorporating adjunct interventions such as topical sirolimus or other targeted agents that modulate the mTOR pathway or integrating multimodal treatments targeting different aspects of angiofibroma pathogenesis, treatment outcomes may be enhanced synergistically.